Below you can find more information about who we partner and collaborate with
PepVax would like to partner with other pharmaceutical and biotechnology companies early in the development process so that we may focus on enhancing our candidates and get it to patients quickly. If you are interested in partnering with us for any of our candidates, please contact us or send us an email directly at firstname.lastname@example.org
PepVax, Inc. have developed a winning strategy to provide the best and most up to date information to the drug development community, while providing a method for this discipline to obtain cutting edge immunotherapy products. If you are interested in licensing a candidate from our immunotherapeutic candidates library, or interested in the peptide design and synthesis, please contact us or send us an email directly at email@example.com
National Human Genome Center
In June 2015, PepVax entered into a Collaborative Research and Development Agreement (CRADA) with Howard University's National Human Genome Center to research and test peptide candidates for breast and prostate cancers using enhanced genome analysis.